Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of intravenous NMU-HbV as a red blood cell substitute in healthy adults (HbV-101b)
jRCT2051240249Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of HbV-101 in anaemia (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety (adverse events) and Medically significant changes within 72 hours. Started May 2025; status: active, not recruiting.
02
Drugs
HbV-101
03
Conditions
anaemia
Beyond the preview
Go deeper on jRCT2051240249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240249.